



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/010,942	12/06/2001	Guriq Basi	ELN-002	5594
959	7590	05/11/2006		
LAHIVE & COCKFIELD 28 STATE STREET BOSTON, MA 02109			EXAMINER BALLARD, KIMBERLY A	
			ART UNIT	PAPER NUMBER
			1649	

DATE MAILED: 05/11/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Examiner-Initiated Interview Summary	Application No.	Applicant(s)	
	10/010,942	BASI ET AL.	
	Examiner	Art Unit	
	Kimberly A. Ballard	1649	

All Participants:

(1) Kimberly A. Ballard.

(2) Janet Andres.

Status of Application: Pending

(3) Debra Milasincic.

(4) Amy Mandragouras.

Date of Interview: 24 April 2004

Time: 4 PM

Type of Interview:

- ☒ Telephonic
☐ Video Conference
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☒ No

If Yes, provide a brief description:

Part I.

Rejection(s) discussed:

Claims discussed:

6, 13, 14, 30-32, 207

Prior art documents discussed:

Part II.

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

See Continuation Sheet

Part III.

- ☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.
☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

Kimberly Ballard
(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: The enablement of claims reciting single light or heavy chains as part of an immunoglobulin was discussed. The enablement of claims reciting less than a definitive number of complementarity determining regions (CDRs) was also discussed. Regarding claim 6, parts (b) and (c), the solved heavy chain structure (OPG2) and the solved heavy chain CDR3 structure (1qkz), as parts of the 3-D model, were discussed.